Equillium to present data supporting CD6-ALCAM at ASH annual meet
Category: #health  | By Nikita Chaurasia  | Date: 2019-11-28 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Equillium to present data supporting CD6-ALCAM at ASH annual meet

Equillium Inc., a clinical-stage biotechnology company, has reportedly announced that it will be presenting positive data related to the role CD6-ALCAM pathway as a relevant target for patients who are suffering from acute graft versus host disease (aGVHD). The company will also be presenting the details of its EQUATE Phase 1b/2 clinical trial design at 61st ASH Annual Meeting, which will be held in Orlando, Florida.

Reportedly, the data representing itolizumab inhibits T cell responses in aGVHD positive patients’ sample. Moreover, it favors itolizumab as a possible systemic therapy which can regulate pathogenic T effector cell activity in an in vivo disease model.

Dr. Jerome Ritz, Exec Director of CMCF at the Dana-Farber Cancer Institute and Prof. of Medicine at Harvard Medical School, said that around 30-70 percent of patients who receive allogeneic HSCT along with standard GVHD prophylaxis regimens are identified with aGVHD. This disorder is a leading cause of non-relapse mortality in patients undergoing allogeneic HSCT. However, there are no approved treatments available for this disease yet. 

Ritz added that they would further research on EQUATE trial. With Dr. Robert Soiffer, he has conducted a study at Dana-Farber over a decade ago that clarified the role of CD6+ T effector cells in the development of aGVHD.

As per Stephen Connelly, Ph.D., Chief Scientific Officer, Equillium, these data show the potential of CD6 blockade to inhibit T effector cell responses, which further supported the company’s ongoing EQUATE Phase 1b/2 clinical trial of itolizumab for front-line treatment in patients who are suffering from aGVHD.

He added that the EQUATE trial is designed to determine the activity and safety of itolizumab. The company is looking forward to sharing positive translational data and study design at ASH Annual Meeting and Exposition and offer future updates of its programs as they progress. 

Source Credit - https://ir.equilliumbio.com/news-releases/news-release-details/equillium-present-translational-data-itolizumab-acute-graft

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Goldman Sachs provides unlimited holidays to its senior employees

Goldman Sachs provides unlimited holidays to its senior employees

By Nikita Chaurasia

Goldman Sachs has recently announced a flexible vacation scheme under which the company’s senior employees can take unlimited paid leaves annually. As per sources, the global investment bank has unveiled a new policy that will allow senior sta...

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...